Completed PHASE3 INTERVENTIONAL 2-arm NCT00397189

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin

Sponsor: Neurim Pharmaceuticals Ltd.

Conditions Primary Insomnia

Interventions Circadin placebo circadin

Updated 6 times since 2017 Last updated: Apr 29, 2018 Started: Oct 31, 2006 Primary completion: Dec 31, 2008 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Insomnia, this trial is completed. The trial is conducted by Neurim Pharmaceuticals Ltd. and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurim Pharmaceuticals Ltd.

Data source: Neurim Pharmaceuticals Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glasgow, United Kingdom